Curaleaf Laboratories and Sanity Group Announce Partnership to Advance Medical Cannabis Innovation in the UK
Curaleaf Laboratories, one of the UK-leading pharmaceutical-grade medical cannabis manufacturers, is delighted to announce a partnership with Berlin-based Sanity Group, a European life science company focused on cannabinoids and wellbeing products.
The partnership brings together Curaleaf Laboratories’ established manufacturing, quality, and commercial capabilities with Sanity Group’s international expertise in cannabinoid-based therapeutics. Together, the companies will collaborate to develop, manufacture, and commercialise innovative medical cannabis products tailored to the needs of UK patients and healthcare professionals.
Under the agreement, Curaleaf Laboratories will leverage its MHRA-approved infrastructure and compliance framework to support the introduction of new formulations, while Sanity Group will contribute its pharmaceutical know-how, intellectual property and experience in building clinically relevant cannabinoid products across global markets.
Richard Hodgson, Managing Director of Curaleaf Laboratories: “This partnership represents a significant step forward in our mission to deliver consistent, pharmaceutical-grade medical cannabis products to patients in the UK. By working with Sanity Group, we are combining complementary strengths to accelerate innovation while maintaining the highest standards of quality, safety, and regulatory compliance.”
Finn Hänsel, Founder and Managing Director of Sanity Group: “The UK is a key strategic market for medical cannabis. Partnering with Curaleaf Laboratories allows us to translate our capabilities into scalable, compliant products that can make a meaningful difference for patients and prescribing clinicians.”
This partnership underscores the continued maturation of the UK medical cannabis market and reflects a shared vision to set new benchmarks for quality, innovation, and patient-centric care.
The first Sanity Group products manufactured under this partnership will be available on prescription by clinicians listed on the UK Specialist Register from Q1 2026.
If you are an interested healthcare professional seeking information on prescribing or ordering, please contact us at info@curaleaflaboratories.co.uk
Patients seeking information from their dispensing pharmacy may visit Curaleaf Pharmacy if applicable. Treatment decisions should be made in consultation with a qualified healthcare professional.
The post Curaleaf Laboratories and Sanity Group Announce Partnership to Advance Medical Cannabis Innovation in the UK appeared first on Business of Cannabis.
Source link
